Key result
Body weight is negatively associated with dabigatran and apixaban trough concentrations, with the strongest association observed in female patients using dabigatran.
Why the study?
Is body weight associated with direct oral anticoagulant trough concentrations in dabigatran and apixaban users?
Cross-Sectional (n=148)
No
Is body weight associated with direct oral anticoagulant trough concentrations in dabigatran and apixaban users?
Effect estimate: -0.173 ng/ml/kg (95% CI -0.35 to -0.11)
Higher body weight may lead to lower trough concentrations of dabigatran and apixaban, which could have implications for dosing in obese patients.
Body weight may influence DOAC trough levels; leaves open whether weight-adjusted dosing improves outcomes.
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
No takes yet. Share an insight, caveat, or question.
Borst et al. (2020) conducted a cross-sectional in Direct oral anticoagulant use (n=148). Body weight was evaluated on Dabigatran trough concentration (-0.173 ng/ml/kg, 95% CI -0.35 to -0.11). Body weight is negatively associated with dabigatran and apixaban trough concentrations, with the strongest association observed in female patients using dabigatran.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: